1351 PREDICTION OF RELAPSE AFTER PEGINTERFERON ALFA-2B/RIBAVIRIN THERAPY IN CHRONIC HCV GENOTYPE 1 PATIENTS IS DEPENDENT ON MINIMAL RESIDUAL VIREMIA BUT NOT ON IL28B GENOTYPE

J. Wiegand,K. Neumann,S. Böhm,V. Weich,H. Klinker,B. Möller,J. Rasenack,H. Hinrichsen,T. Gerlach,U. Spengler,P. Buggisch,C. Sarrazin, T. Berg

Journal of Hepatology（2011）

Cited 1|Views11

No score

Abstract

Week 4 (log10 decline) Week 12 (log10 decline) <0.5 0.5-1.01.0-2.0>2.0 <2 ≥2.0 ETR 4/31 (13%) 20/53 (38%) 84/100 (84%) 184/192 (96%) 4/57 (7%) 155/176 (88%) SVR 2/4 (50%) 13/20 (65%) 51/84 (61%) 143/184 (78%) 1/4

Translated text

Key words

chronic hcv genotype,alfa-2b/ribavirin therapy,residual viremia,peginterferon,relapse

AI Read Science

Must-Reading Tree

Example

Generate MRT to find the research sequence of this paper

Chat Paper

Summary is being generated by the instructions you defined